Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial — Douglas S. Goodin (2011) | RDL Network
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial
Article 2011 en
Authors
DG
Douglas S. Goodin
HH
Hans-Peter Hartung
PO
Paul O’Connor
Abstract
1 min read
There was a notable dissociation between the impact of NAbs on MRI and clinical outcomes. On MRI measures, the impact was consistent and convincing, whereas on clinical measures a negative impact of NAbs was not found. The basis for this clinico-radiographic paradox is unknown but it suggests that the relationship between NAbs and the therapeutic effects of IFNβ-1b is complex.
P. D. Molyneux, Ludwig Kappos, Chris H. Polman, Carlo Pozzilli, Frederik Barkhof, Massimo Filippi, Tarek Yousry, David W. Hahn, Klaus Wagner, Mahdiyeh Khabbaz Koche Ghazi, K. Beckmann, Frank Dahlke, Nicholas Losseff, Gareth J. Barker, Alan J. Thompson, D. H. Miller
Kathryn C. Fitzgerald, Kassandra L. Munger, Karl Köchert, Barry G.W. Arnason, Gıancarlo Comı, Stuart D. Cook, Douglas S. Goodin, Massimo Filippi, Hans-Peter Hartung, Douglas Jeffery, Paul O’Connor, Gustavo Cruz, Rupert Sandbrink, Ludwig Kappos, Christoph Pohl, Alberto Ascherio
Hans-Peter Hartung, Ludwig Kappos, Douglas S. Goodin, Paul O’Connor, Massimo Filippi, Barry G.W. Arnason, Giancarlo Comi, Stuart D. Cook, Douglas Jeffery, John Petkau, Richard White, Timon Bogumil, K. Beckmann, Brigitte Stemper, Gustavo Cruz, Rupert Sandbrink, Christoph Pohl
P. D. Molyneux, Gareth J. Barker, Frederik Barkhof, K. Beckmann, Frank Dahlke, Massimo Filippi, Mahdiyeh Khabbaz Koche Ghazi, David W. Hahn, Deirdre MacManus, Chris H. Polman, Carlo Pozzilli, Ludwig Kappos, Alan J. Thompson, Klaus Wagner, Tarek Yousry, D. H. Miller
Discussion(0)
No comments yet. Be the first to comment.